AAD
Author: Willhemenia Loremipsum Special session: Lorem ipsum dolor sit amet Category: Lorem ipsum View all results

Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.

  • Presentation

HS as a Systemic Disease: Examining Comorbidities in Pediatric Patients

Description

The presentation highlights the systemic nature of hidradenitis suppurativa (HS) in pediatric patients, emphasizing the importance of recognizing and screening for associated comorbidities. Over the past decade, there has been significant growth in research on pediatric HS, revealing that HS is linked with various comorbidities affecting up to 93% of patients, similar to adults. It outlines three patient scenarios: those who come for unrelated skin issues, those with a confirmed HS diagnosis, and those requiring ongoing care. The speaker underscores the necessity for dermatologists to be proactive in screening for HS in patients presenting with severe acne, obesity, and other associated disorders. Key comorbidities include psychiatric conditions, endocrine abnormalities like precocious puberty and polycystic ovarian syndrome, and metabolic issues, particularly obesity, which affects a significant portion of HS patients. Other considerations include inflammatory bowel disease and associated joint issues. The speaker advocates for a multidisciplinary approach to care, ensuring consistent screening for comorbidities at diagnosis and during follow-ups. Emphasis is placed on the need for better screening tools specifically tailored for pediatric HS patients and encourages involvement in collaborative research efforts to improve management practices.

View more

Conclusions

  • Hidradenitis suppurativa (HS) is increasingly recognized as a systemic disease with numerous associated comorbidities in pediatric patients.
  • Screening for HS should be integrated into dermatology practices, particularly for patients with related conditions such as severe acne and obesity.
  • Comorbidities associated with HS are prevalent in pediatric patients, including obesity, inflammation, anxiety, depression, and racial disparities in prevalence rates.
  • Pediatric HS patients may demonstrate increased hormonal imbalances, metabolic syndrome, and endocrine disorders, warranting thorough investigation and monitoring.
  • There is a significant association between HS and inflammatory bowel disease (IBD) and inflammatory joint diseases in pediatric patients.
  • Psychiatric disorders, including anxiety and depression, are notably more prevalent in pediatric patients with HS than in the general population.
  • Ongoing screening and reassessment for comorbidities are essential in the management of pediatric patients with HS, as these conditions can develop over time.
  • Multidisciplinary care is crucial for the effective treatment of HS and its associated comorbidities, and continued research is needed to enhance understanding and management practices.
  • J Am Acad Dermatol 2020; 86(1): 140-7.
  • JAMA Dermatol. 2021; 157(4):385-391.
  • JAMA Derm. 2021; 157 (9): 1095-1101.
  • J Invest Dermatol. 2018;138(6):1288-92.
  • J Am Acad Dermatol. 2018; 79(3): 514-9.
  • JEADV 2021; 35: 345:52.
  • The Lancet 2022; 6(3): 138-9.
  • Ped Derm. 2021; 38: 98-102.
  • Ann Transl Med 2020; 8(13):821.
  • J Gen Intern Med. 2001;16(9):606-613.
  • Ped Derm 2017; 34: 461-4.
  • Dermatol 2018; 178: 697-703.
  • Dermatol Basel Switz 2018; 234(1-2): 66-70.
  • J Am Acad Dermatol. 2022; 86(5): 1092-101.